The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is set to witness a CAGR of more than 3%, during the forecast period. The market is estimated to reach a value of more than USD 36 Billion by 2030.

Dipeptide Peptidase 4 (DPP) 4 Inhibitors Market Overview:

A dipeptidyl peptidase 4 (DPP-4) inhibitor is a class of medicine used to lower high blood sugar levels and treat type 2 diabetes. These inhibitors work to reduce blood sugar levels by increasing levels of incretin, which increases insulin secretion.

Rising prevalence of diabetes and related complications such as cardiovascular disease, nephropathy, retinopathy, and neuropathy, and growing geriatric population fuel the market growth. However, side effects of drugs such as urinary tract infections and respiratory infections limit the market growth.

Dipeptide Peptidase 4 (DPP) 4 Inhibitors market size, estimates and forecasts are provided in terms of sales volume (K units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Dipeptide Peptidase 4 (DPP) 4 Inhibitors market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.

Key Market Updates:

• In July 2022, Glenmark Pharmaceuticals Limited announced the launch of a fixed dose combination (FDC) with sitagliptin for adults with type 2 diabetes in India. Glenmark has launched eight combinations of sitagliptin-based drugs and affordable variants under the brand name SITAZIT®.
• With the patent expiry of the Merck & Co drug Januvia/Janumet (sitagliptin) approaching in May 2022, India's drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), has set the price for a fixed-dose combination of several antidiabetic drugs under the patented component 50 % Sale.

Major Market Segments Covered in Dipeptide Peptidase 4 (DPP) 4 Inhibitors Industry Research:

Market Key Players:
Sanofi, Takeda Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim

By Type:

• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin
• Vildagliptin

By Application:

• Hospitals
• Clinics

By Region:

Asia Pacific holds the highest market share in the dipeptide peptidase 4 (DPP-4) inhibitors market and is expected to register a CAGR of over 4% during the forecast period.

The use of oral antidiabetic drugs is increasing due to the fact that next-generation oral drugs such as DPP-4 and SGLT-2 reduce cardiovascular risk in diabetic patients. In the Asia Pacific region, China and Japan have been recognized as potential developing markets due to the growing diabetic population in these regions. Japan is a mature market and has several associated challenges, such as slowing economic growth, an aging population, and intensifying competition. China has the largest market share and is expected to grow steadily at a CAGR of 4%. The country is witnessing a significant increase in the number of generic drug manufacturers. Additionally, major global players in the research market are facing stiff competition from regional players.

The market is expected to grow during the forecast period due to the aforementioned factors.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Dipeptide Peptidase 4 (DPP) 4 Inhibitors Market report scope:

Key Takeaways from this Dipeptide Peptidase 4 (DPP) 4 Inhibitors Report

• Estimate Dipeptide Peptidase 4 (DPP) 4 Inhibitors market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, applications and by different industry verticals.
• Understand the supply chain in depth on the value growth at each step, in order to optimize value and bring effectiveness in your processes.
• Know the different dynamics affecting the market - challenges, key driving factors and opportunities.
• Get a quick viewpoint on the Dipeptide Peptidase 4 (DPP) 4 Inhibitors market entropy - M&A's, deals, partnerships, product launches of all key companies for the historical 5 years.
• Estimate the supply-demand gaps, import-export data and regulatory landscape for more than top 20 countries worldwide for the market.
• Get complete insights on your competitor performance - market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
• Study the sales and distribution channels over key geographies to improve top-line revenues.

Frequently Asked Questions-

What is the CAGR of Dipeptide Peptidase 4 (DPP) 4 Inhibitors market?

The Dipeptide Peptidase 4 (DPP) 4 Inhibitors Market is growing at a CAGR of 3% During Forecast Period.

 What are the key types of Dipeptide Peptidase 4 (DPP) 4 Inhibitors market?

Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What are the key applications of Dipeptide Peptidase 4 (DPP) 4 Inhibitors market?

Hospitals, Clinics                                                                        

Who are the key players in Dipeptide Peptidase 4 (DPP) 4 Inhibitors market?

Sanofi, Takeda Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim